Gonadorelin, also known as gonadotropin-releasing hormone (GnRH), is a hormone that plays a vital role in the regulation of reproductive functions. It is produced by the hypothalamus in the brain and acts on the pituitary gland to stimulate the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are essential for the development and maturation of the ovaries in females and the testes in males.

Gonadorelin is commonly used in medical settings to diagnose and treat various reproductive disorders. It can be administered via injection or nasal spray. In fertility treatments, gonadorelin can help stimulate ovulation in women who have irregular menstrual cycles or have difficulty conceiving. In men, it can be used to enhance sperm production.

Source: PubChem

• Sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
• Molecular Formula: C55H75N17O13
• Molecular Weight: 1182.311 g/mol
• PubChem CID: 638793
• CAS Number: 9034-40-6
• Synonyms: Growth Hormone Releasing Factor, Somatocrinin, Somatoliberin

Gonadorelin Research and Breast Cancer Prevention

Gonadorelin research has shown potential in breast cancer prevention through various mechanisms.

Raloxifene and antiestrogenic gonadorelin: A study published in Cancer Prevention Research found that both raloxifene and gonadorelin inhibit intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. This suggests a potential role for gonadorelin in cancer prevention.

Gonadorelin and micrometastatic breast cancer: According to a study published on PMC, gonadorelin can occupy the receptors for gonadorelin in the pituitary gland, potentially preventing the recurrence of micrometastatic breast cancer.

Targeted drug delivery for breast cancer: Functionalized liposomes have been studied as a delivery system for targeted breast cancer drug delivery. This approach shows promise in improving treatment strategies for breast cancer.

Hormone agonists for breast cancer prevention: Hormone agonists, such as gonadorelin and goserelin, have been explored as potential options for breast cancer prevention. Economic studies have evaluated the cost-effectiveness of these prevention strategies.

Ovarian ablation with gonadorelin analog: An article published in Nature discusses the proposal of temporary ovarian ablation using a gonadorelin analog as a preventive strategy for breast cancer. This study aims to determine the effects of risk factors and prevention strategies on breast cancer development.

Gonadorelin a Breakthrough in Prostate Cancer

New breakthroughs in the treatment of prostate cancer have emerged, including the use of Gonadorelin. This hormone therapy has shown promising results in lowering testosterone levels in certain patients with prostate cancer. By reducing testosterone levels, which is necessary for cancer cell growth, Gonadorelin may help slow down or even stop the progression of the disease.

According to a study published in the Journal of Urology, testosterone breakthrough rates during androgen deprivation therapy (ADT) for castration-sensitive prostate cancer were observed to be significantly reduced with the use of Gonadorelin. This indicates the potential effectiveness of Gonadorelin in suppressing testosterone levels and managing the disease.

The FDA has also approved the first oral hormone therapy for advanced prostate cancer, which further supports the potential benefits of hormone therapies like Gonadorelin in treating this condition. These hormone therapies, including ADT, aim to halt testosterone production or block its effects on prostate cancer cells.

The impact of gonadorelin and GnRH analogues on testosterone levels
Source: PubMed

Gonadorelin May Reduce Dementia Risk

Recent studies have suggested that Gonadorelin, a gonadotropin-releasing hormone (GnRH) agonist, may play a role in reducing the risk of dementia. Dementia is a progressive neurological disorder characterized by a decline in cognitive function, memory loss, and impaired daily functioning. It affects millions of people worldwide, with Alzheimer’s disease being the most common form.

One study published in the National Center for Biotechnology Information (NCBI) found a potential link between the use of GnRH agonists and a reduced risk of dementia or Alzheimer’s disease. The study compared different types of androgen deprivation therapy and their association with dementia risk. Interestingly, the use of antiandrogen monotherapy was associated with an increased risk of dementia or Alzheimer’s disease. In contrast, GnRH agonist use and orchiectomy (surgical removal of the testicles) were not linked to an elevated risk.

Another review published in PMC explored alternative treatment options for Alzheimer’s disease, including targeting the release of luteinizing hormone (LH), which GnRH regulates. The review suggested that targeting LH release through the use of GnRH agonists could be a successful strategy in preventing or delaying the progression of Alzheimer’s disease.

Furthermore, hormone replacement therapy (HRT) has also been implicated in reducing the risk of dementia. A study mentioned by CNN found that taking hormone replacement therapy at the right time in midlife can reduce the risk of dementia and Alzheimer’s disease by 23% to 32%.

While some studies suggest a potential protective effect of hormonal therapies like Gonadorelin and HRT on dementia risk, it is important to note that research findings on this topic have been inconclusive and contradictory at times. More research is needed to fully understand the relationship between these therapies and dementia risk.

Gonadorelin has long been used in the treatment of human and animal diseases, but ongoing research continues to unveil fascinating insights into the functioning of GnRH and GnRH analogues in both normal physiology and disease development. One particularly groundbreaking discovery has been the potential of gonadorelin in the treatment of prostate cancer, leading to the development of an exceptionally effective cure. Thanks to early detection, doctors have achieved a remarkable 99% cure rate for patients with prostate cancer.

Similar breakthroughs may be on the horizon as researchers delve into the significant role of gonadorelin and its downstream hormones in the pathways associated with the risk of Alzheimer’s disease.

It’s important to highlight that gonadorelin demonstrates minimal side effects and exhibits excellent subcutaneous bioavailability in mice, making it a promising candidate for further exploration. However, it’s essential to note that dosages per kilogram in mice do not directly translate to humans. Additionally, it’s crucial to mention that gonadorelin, available for purchase at Peptide Shop, is strictly limited to educational and scientific research purposes, and it is not intended for human consumption. Therefore, only licensed researchers should consider acquiring gonadorelin for their research endeavors.

Please note that all the articles and product information provided on this website are intended for informational and educational purposes only.

The products offered on this platform are specifically designed for in-vitro studies, meaning they are conducted outside the body. It is important to clarify that these products are not medicines or drugs, and the FDA has not approved them for the prevention, treatment, or cure of any medical condition, ailment, or disease.

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Dr. Giorgio Secreto currently studies at the IRCCS National Cancer Institute in Italy. His accolades include, a 1963 High School degree, Maturità Classica 1969 Degree in Medicine and Surgery, University of Milan, Italy 1974 Degree Specialist in Endocrinology, University of Turin, Italy. Doctor Secreto has been working at the National Cancer Institute of Milan since 1970 up to now, after his retirement in December 2010. The role of androgens in breast cancer is his main field of study.

He has been teacher at the Italian School of Senology (1989-1996), Associate Professor in Oncology, L.U.de.S. University, Lugano, Switzerland (1999-2008), and Associate Professor in Endocrinology, Nurses’ School, University of Milan (2003-2008). He is active member of the New York Academy of Sciences and the American Association for the Advancement of Sciences. He published about 100 papers, including a few that pertain to GnRH’s effects on the reduction of breast cancer via minimizing excessive androgens.

Dr. Giorgio Secreto is being referenced as one of the leading scientists involved in the research and development of Gonadorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Doctor Secreto is listed in [1] and [3] under the referenced citations.

1. G. Secreto et al., “A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women,” Breast Cancer Res. Treat., vol. 158, no. 3, pp. 553–561, 2016.
2. D. V. Spicer and M. C. Pike, “Sex steroids and breast cancer prevention,” J. Natl. Cancer Inst. Monogr., no. 16, pp. 139–147, 1994.
3. G. Secreto, P. Muti, M. Sant, E. Meneghini, and V. Krogh, “Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy,” Endocr. Relat. Cancer, vol. 24, no. 11, pp. C21–C29, 2017.
4. E. S. Vollaard, A. P. van Beek, F. A. J. Verburg, A. Roos, and J. A. Land, “Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin,” J. Clin. Endocrinol. Metab., vol. 96, no. 5, pp. 1197–1201, May 2011.
5. F. Labrie, “Hormonal therapy of prostate cancer,” Prog. Brain Res., vol. 182, pp. 321–341, 2010.
6. F. Labrie, “GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer,” Endocr. Relat. Cancer, vol. 21, no. 4, pp. R301-317, Aug. 2014.
7. F. Labrie, “Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology,” J. Steroid Biochem. Mol. Biol., vol. 145, pp. 144–156, Jan. 2015.
8. F. Labrie, “[Keyrole of endocrinology in the victory against prostate cancer],” Bull. Cancer (Paris), vol. 93, no. 9, pp. 949–958, Sep. 2006.
9. V. Burnham, C. Sundby, A. Laman-Maharg, and J. Thornton, “Luteinizing hormone acts at the hippocampus to dampen spatial memory,” Horm. Behav., vol. 89, pp. 55–63, 2017.
10. C. V. Rao, “Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women,” Reprod. Sci. Thousand Oaks Calif, vol. 24, no. 3, pp. 355–368, 2017.
11. J. Lin et al., “Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease,” J. Neuropathol. Exp. Neurol., vol. 69, no. 3, pp. 253–261, Mar. 2010.
12. R. L. Bowen, T. Butler, and C. S. Atwood, “Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer’s Disease,” J. Clin. Oncol., vol. 34, no. 23, p. 2800, Aug. 2016.
13. M. A. Smith, R. L. Bowen, R. Q. Nguyen, G. Perry, C. S. Atwood, and A. A. Rimm, “Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data,” J. Alzheimers Dis. JAD, vol. 63, no. 4, pp. 1269–1277, 2018.
14. A. Cáceres, J. E. Vargas, and J. R. González, “APOE and MS4A6A interact with GnRH signaling in Alzheimer’s disease: Enrichment of epistatic effects,” Alzheimers Dement. J. Alzheimers Assoc., vol. 13, no. 4, pp. 493–497, Apr. 2017.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.